ArriVent BioPharma (AVBP) Assets Average (2024 - 2026)

ArriVent BioPharma has disclosed Assets Average across 3 years of filings, most recently posting $341.2 million for Q1 2026.

• Assets Average for Q1 2026 came in at $341.2 million, up 39.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $341.2 million (up 39.15% YoY), and the FY2025 annual result was $304.1 million, up 38.83% from the prior year.
• Assets Average came in at $341.2 million for Q1 2026 at ArriVent BioPharma, up from $329.9 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $341.2 million in Q1 2026 to a low of $242.5 million in Q2 2025.
• The 3-year median for Assets Average is $298.0 million (2025), against an average of $289.5 million.
• Across the five-year window, Assets Average decreased 23.82% in 2025 and surged 39.15% in 2026, its largest moves.
• ArriVent BioPharma's Assets Average stood at $283.8 million in 2024, then grew by 16.22% to $329.9 million in 2025, then advanced by 3.45% to $341.2 million in 2026.
• The last three Assets Average figures came in at $341.2 million (Q1 2026), $329.9 million (Q4 2025), and $298.0 million (Q3 2025), per Business Quant data.